{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:03Z","timestamp":1783577703986,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.4158\/ep161678.ra","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T17:08:54Z","timestamp":1493312934000},"page":"841-856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Stewart G.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supraja","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP161678.RA_bb0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP161678.RA_bb0020","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.4158\/EP161678.RA_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in postmenopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.4158\/EP161678.RA_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0040","first-page":"658","article-title":"Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis","volume":"17","author":"Migliore","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.4158\/EP161678.RA_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0050","unstructured":"FRAX. 2016;. www.shef.ac.uk\/frax\/"},{"key":"10.4158\/EP161678.RA_bb0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.4158\/EP161678.RA_bb0060","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/j.clinthera.2012.12.012","article-title":"New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity","volume":"35","author":"Taylor","year":"2013","journal-title":"Clin Ther"},{"key":"10.4158\/EP161678.RA_bb0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.2015.7032","article-title":"Costs associated with using different insulin preparations","volume":"314","author":"Tylee","year":"2015","journal-title":"JAMA"},{"key":"10.4158\/EP161678.RA_bb0070","unstructured":"MIX 2.0. Professional software for meta-analysis in Excel. Version (2.0.1.4). BiostatXL, 2011. Available at: http:\/\/www.meta-analysis-made-easy.com. Accessed May 12, 2017."},{"key":"10.4158\/EP161678.RA_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2288-6-50","article-title":"Development and validation of MIX: comprehensive free software for meta-analysis of causal research data","volume":"6","author":"Bax","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.4158\/EP161678.RA_bb0080","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.4158\/EP161678.RA_bb0085","series-title":"Cochrane Handbook for Systematic Review of Intervention","first-page":"243","article-title":"Analysing data and understandign meta-analysis","author":"Deeks","year":"2008"},{"key":"10.4158\/EP161678.RA_bb0090","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0095","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.4158\/EP161678.RA_bb0100","unstructured":"Java Applets for Power and Sample Size [Computer software]. 2006\u20139. (Accessed May, 2016. Lenth, RV (2006\u20139). Java Applets for Power and Sample Size [Computer software]. Retrieved from http:\/\/www.stat.uiowa.edu\/~rlenth\/Power."},{"key":"10.4158\/EP161678.RA_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP161678.RA_bb0110","first-page":"97","article-title":"Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study","volume":"8","author":"Muscoso","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.4158\/EP161678.RA_bb0115","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP161678.RA_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP161678.RA_bb0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International","volume":"255","author":"Sambrook","year":"2004","journal-title":"J Intern Med"},{"key":"10.4158\/EP161678.RA_bb0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","article-title":"Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis","volume":"11","author":"Luckey","year":"2004","journal-title":"Menopause"},{"key":"10.4158\/EP161678.RA_bb0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.4158\/EP161678.RA_bb0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3349\/ymj.2008.49.1.119","article-title":"Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis","volume":"49","author":"Iwamoto","year":"2008","journal-title":"Yonsei Med J"},{"key":"10.4158\/EP161678.RA_bb0150","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0155","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.4158\/EP161678.RA_bb0160","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP161678.RA_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP161678.RA_bb0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00223-014-9927-7","article-title":"Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study","volume":"95","author":"Hagino","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP161678.RA_bb0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.4158\/EP161678.RA_bb0185","first-page":"1953","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0190","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.4158\/EP161678.RA_bb0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0200","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP161678.RA_bb0205","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4158\/EP161678.RA_bb0210","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.4158\/EP161678.RA_bb0215","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0220","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0225","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00198-008-0767-z","article-title":"Effect of alendronate in elderly patients after low trauma hip fracture repair","volume":"20","author":"Cecilia","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0230","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.4158\/EP161678.RA_bb0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-1241.2001.tb11111.x","article-title":"Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis","volume":"55","author":"Dursun","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.4158\/EP161678.RA_bb0240","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0245","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0250","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0260","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/mds.20825","article-title":"Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial","volume":"21","author":"Sato","year":"2006","journal-title":"Mov Disord"},{"key":"10.4158\/EP161678.RA_bb0265","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","article-title":"A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis","volume":"7","author":"Clemmesen","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0270","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0275","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP161678.RA_bb0280","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"key":"10.4158\/EP161678.RA_bb0285","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0290","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0295","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis Int"},{"key":"10.4158\/EP161678.RA_bb0300","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/01.WNL.0000152871.65027.76","article-title":"Risedronate therapy for prevention of hip fracture after stroke in elderly women","volume":"64","author":"Sato","year":"2005","journal-title":"Neurology"},{"key":"10.4158\/EP161678.RA_bb0305","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.165.15.1737","article-title":"The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial","volume":"165","author":"Sato","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP161678.RA_bb0310","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss","volume":"44","author":"McClung","year":"2009","journal-title":"Bone"},{"key":"10.4158\/EP161678.RA_bb0315","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.4158\/EP161678.RA_bb0320","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0325","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP161678.RA_bb0330","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial","volume":"13","author":"Lufkin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0335","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","article-title":"Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161678.RA_bb0340","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archinte.164.8.871","article-title":"A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women","volume":"164","author":"Reid","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP161678.RA_bb0345","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0350","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0355","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0360","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0365","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","article-title":"Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases","volume":"47","author":"Miyauchi","year":"2010","journal-title":"Bone"},{"key":"10.4158\/EP161678.RA_bb0370","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0375","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161678.RA_bb0385","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0390","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.4158\/EP161678.RA_bb0395","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/jc.2008-2241","article-title":"The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women","volume":"94","author":"Grey","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161678.RA_bb0400","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161678.RA_bb0405","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20357785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20357785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:03:32Z","timestamp":1761516212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20357785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1530891X20357785"],"URL":"https:\/\/doi.org\/10.4158\/ep161678.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP161678.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}